Jabil (JBL) announced the acquisition of Pharmaceutics International, completed February 3. “Jabil is very pleased to announce this ...

With one foot already in the healthcare realm, multi-industry manufacturer Jabil is beefing up its biopharma bona fides with ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

NLS Pharmaceutics stock is trading higher on Friday after the company announced its merger with Kadimastem has been approved by Kadimastem shareholders.

NLS Pharmaceutics AG’s profitability metrics reveal strong financial health. The company currently boasts a gross margin of -71.63%. The profit margin, also known as the revenue ratio or gross profit ...

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous ...

NLS Pharmaceutics AG (NLSP) stock has hit a 52-week low, trading at $1.73, with a market capitalization of just $2.94 million ...

Shareholders of the Israeli bio-pharmaceutical startup, Kadimastem Ltd. approved the companys merger with the Swiss ...

RSC Pharmaceutics acknowledges how chemistry and related disciplines can make a big difference. This impactful journal provides you with a platform to publish crucial research on pharmaceutics. This ...

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system ...

Keep learning. Excel in your career. Choose from more than 200 courses in seven different categories, taught by experts in the chemistry community, online and in person.

ZURICH, Jan. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company ...